Publications by authors named "Maria F Botero"
Article Synopsis
- HER2-targeted therapies trastuzumab (T) and lapatinib (L) are effective against HER2-positive breast cancer, but many patients develop resistance, prompting this study to explore the mechanisms behind this resistance.
- A panel of 13 HER2-positive cell lines was used to evaluate resistance, identifying both de novo and acquired resistance through long-term drug exposure, while assessing hormone receptor (ER) pathway interactions and cellular responses to different treatments.
- Findings revealed that increased levels of ER or its products were linked to resistance, and while L-resistant lines could still be targeted through HER2 inhibition, they eventually shifted reliance from ER to the HER network, complicating treatment strategies with potential therapeutic implications for combining endocrine
Background: Young adult Mexican Americans (MA) exhibit lower insulin sensitivity (Si) than nonHispanic whites (NHW), even when controlling for fitness and adiposity. It is unclear if MA are as responsive to the same lifestyle intervention as NHW.
Objective: We developed a model to examine cardiometabolic plasticity (i.
Nanoparticle-based therapeutics with local delivery and external electromagnetic field modulation holds extraordinary promise for soft-tissue cancers such as breast cancer; however, knowledge of the distribution and fate of nanoparticles in vivo is crucial for clinical translation. Here we demonstrate that multiple diagnostic capabilities can be introduced in photothermal therapeutic nanocomplexes by simultaneously enhancing both near-infrared fluorescence and magnetic resonance imaging (MRI). We track nanocomplexes in vivo, examining the influence of HER2 antibody targeting on nanocomplex distribution over 72 h.
View Article and Find Full Text PDF